Eli Lilly Found a New Gear. You Paid For It.

Beyond strong drugs, the stock’s ascent was powered by its notable profitability.

You watched Eli Lilly (LLY) climb 76% in a year, crushing the broader market’s 19.3% gain. You probably assume you know why: two drugs, Mounjaro and Zepbound, are generating unprecedented revenue streams. And you’re right, but that’s like saying a rocket flies because of the fire at the bottom. The real story, the one that justified a trillion-dollar valuation, is about the sheer force that fire is generating.

The year’s strong sales told only part of the story. More significantly, Eli Lilly hit a new level of financial performance as its growth actually began to accelerate.

How Fast Is The Core Business Actually Growing?

Let’s start with the latest quarter. Revenue shot up 48% compared to the same period in 2025. The company’s incretin drugs, Mounjaro and Zepbound, combined for $14.9 billion in revenue in a single quarter. But look at the bigger picture: over the last 12 months, revenue growth hit 50%. That’s a significant step up from the company’s 3-year average growth rate of 39%. When a company this large finds a way to grow faster, you pay attention. Management was confident enough to raise its full-year revenue forecast by $3 billion on the low end.

But Isn’t This Just A One-Trick Pony?

A fair question. When one franchise drives the numbers this hard, you look for what’s next. Over the past year, Lilly provided an answer. The company announced positive results from 3 Phase 3 trials for its next-generation obesity treatment, retatrutide. The data showed what management called “profound levels of weight loss,” with one trial demonstrating results “approaching bariatric surgery levels.” That single development significantly strengthens Lilly’s long-term pipeline, indicating potential beyond its current portfolio. The company also went shopping, announcing acquisitions like CrossBridge Bio and AtaiBeckley to build out its pipeline in other areas.

The market for these drugs is large, with management noting that treatment for obesity is still in the “mid-single digit” range of penetration. But the addressable market also got a huge boost this year. On July 1, the Medicare GLP-1 Bridge program launched, giving “20 million eligible Americans insurance coverage for GLP-1s for obesity.” That single program meant “35% more people now have coverage for our obesity medicines in the United States.” It was a clear signal that access, a major barrier to growth, was starting to fall.

What About The Profitability Of That Growth?

This might be the most overlooked part of the story. It’s one thing to grow revenue; it’s another to do it this profitably. Lilly’s operating margin now stands at 50%, a huge leap from its 3-year average of 39%. This explosion in profitability raises its own questions, and we recently analyzed whether Eli Lilly can keep the margin you are now paying for. That high margin is partly supported by a net price on Zepbound that an analyst pegged at around $580 per prescription, well above its key competitor. That’s a powerful lever for now, but also a point of focus for bears.

You’ve paid for a perfect growth story, but even with management raising full-year guidance to $85–$87 billion, that forecast implies a 30% to 34% growth rate—a clear step down from the 50% pace delivered over the last twelve months.

Does This Run Have Staying Power?

Knowing why a stock ran is one thing; knowing whether the run has legs is another. The most durable moves are the ones a rising forecast is actually backing, rather than a good week of sentiment. Our Guidance Momentum screen tracks the S&P 500 names where a raised outlook meets real price momentum, so you can judge which runs are built to last. If you would rather own the whole theme than ride this one winner, a healthcare ETF like XLV holds the entire group.

How Do You Compound A Move Like This?

Catching the reason behind a run is a good skill; relying on catching the next one is a risky plan. Durable returns come from owning quality with discipline and letting the winners do the work over time, rather than betting the outcome on a single name and a single catalyst.

That is exactly how the Trefis High Quality (HQ) Portfolio is run. It weighs the full picture of quality across thousands of names, holds the 30 strongest, and sizes and re-balances them with rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.